SUPPLY AND SERVICES AGREEMENTSupply and Services Agreement • November 16th, 2009 • Lorus Therapeutics Inc • Biological products, (no disgnostic substances) • Ontario
WHEREAS pursuant to the terms of an asset purchase agreement made as of the date hereof and certain related transactions, EMBI acquired sole and absolute ownership in certain intellectual property relating to the extraction of a product from bovine bile and known by the trade name “Virulizin”;
SETTLEMENT AGREEMENTSettlement Agreement • November 16th, 2009 • Lorus Therapeutics Inc • Biological products, (no disgnostic substances) • Ontario
WHEREAS on October 6, 2004, Lorus Therapeutics Inc. (formerly 4325231 Canada Inc.) (“Old Lorus”), GeneSense Technologies Inc. (“GeneSense”) and TEMIC entered into a subscription agreement (as amended, restated, supplemented or otherwise modified from time to time, the “Subscription Agreement”) providing for the issuance of three (3) five million dollar ($5,000,000) principal amount convertible debentures (each a “Debenture” and collectively, the “Debentures”) on each of October 6, 2004, January 14, 2005 and April 15, 2005, each maturing on October 6, 2009;
ANIMAL RIGHTS LICENSE AGREEMENTAnimal Rights License Agreement • November 16th, 2009 • Lorus Therapeutics Inc • Biological products, (no disgnostic substances) • Ontario
WHEREAS Lorus and The Erin Mills Investment Corporation ("TEMIC") have entered into a settlement agreement (the "Settlement Agreement") and an asset sale agreement (the "Asset Sale Agreement"), each dated as of the date hereof which, among other things, provide that TEMIC or its nominee are to be assigned certain intellectual property relating to the extraction of a product from bovine bile marketed in association with the trademark "Virulizin" as evidenced by the patents, trademarks and other intellectual property rights (including without limitation, the Patent Rights, as defined below) described in Schedule "A" hereto";
AMENDMENT, ASSIGNMENT, ASSUMPTION, NOVATION AND CONSENT AGREEMENTNovation and Consent Agreement • November 16th, 2009 • Lorus Therapeutics Inc • Biological products, (no disgnostic substances) • Ontario
WHEREAS on October 6, 2004, Lorus Therapeutics Inc. (formerly 4325231 Canada Inc.) ("Old Lorus"), GeneSense Technologies Inc. ("GeneSense") and TEMIC entered into a subscription agreement providing for the issuance of three (3) five million dollar ($5,000,000) principal amount convertible debentures (each a "Debenture" and collectively, the "Debentures") on each of October 6, 2004, January 14, 2005 and April 15, 2005, each maturing on October 6, 2009;
ASSET PURCHASE AGREEMENT BETWEEN LORUS THERAPEUTICS INC. AND THE ERIN MILLS INVESTMENT CORPORATION MADE AS OF June 19, 2009Asset Purchase Agreement • November 16th, 2009 • Lorus Therapeutics Inc • Biological products, (no disgnostic substances) • Ontario
SHARE PURCHASE AGREEMENT BETWEEN THE ERIN MILLS INVESTMENT CORPORATION AND LORUS THERAPEUTICS INC. MADE AS OF JUNE 19, 2009Share Purchase Agreement • November 16th, 2009 • Lorus Therapeutics Inc • Biological products, (no disgnostic substances) • Ontario
